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Adult stem cells have an enormous potential for clin-
ical use in regenerative medicine that avoids many of
the drawbacks characteristic of embryonic stem cells
and induced pluripotent stem cells. In this context,
easily obtainable human adipose-derived stem cells
offer an interesting option for future strategies in
regenerative medicine. However, little is known
about their repertoire of differentiation capacities,
how closely they resemble the target primary tissues,
and the potential safety issues associated with their
use. DNA methylation is one of the most widely rec-
ognized epigenetic factors involved in cellular iden-
tity, prompting us to consider how the analyses of
27,578 CpG sites in the genome of these cells under
different conditions reflect their different natural his-
tory. We show that human adipose-derived stem cells
generate myogenic and osteogenic lineages that share
much of the DNA methylation landscape characteris-
tic of primary myocytes and osteocytes. Most impor-
tant, adult stem cells and in vitro–generated myocytes
and osteocytes display a significantly different DNA
methylome from that observed in transformed cells
from these tissue types, such as rhabdomyosarcoma
and osteosarcoma. These results suggest that the
plasticity of the DNA methylation patterns plays an
important role in lineage commitment of adult stem
cells and that it could be used for clinical purposesas a biomarker of efficient and safely differentiated
cells. (Am J Pathol 2012, 181:2079–2093; http://dx.doi.org/
10.1016/j.ajpath.2012.08.016)
Human adipose-derived stem cells (hASCs) refer to the
plastic-adherent and multipotent cell population isolated
from collagenase digests of adipose tissue. Although the
differentiation capacity of hASCs was initially thought to
be limited to their tissue of origin, recent data have dem-
onstrated that multipotent stem cells retain a broad dif-
ferentiation potential. hASCs can be induced to differen-
tiate along several mesenchymal tissue lineages,
including adipocytes, osteoblasts, myocytes, and chon-
drocytes.1–3 hASCs also differentiate into neuron-like
cells expressing neuronal markers.4–6 The differentiation
ability of hASCs has generated interest because of their
potential clinical use in regenerative medicine.7 They
meet the criteria for application in regenerative medicine
in the following ways: i) they are found in abundant quan-
tities, ii) they can be collected and harvested by a mini-
mal invasive procedure, iii) they can be differentiated into
multiple cell lineage pathways in a reproducible manner,
and iv) they can be safely and effectively transplanted
into an autologous or allogenic host.8
Gene expression potential in stem cell differentiation is
regulated by epigenetic processes that confer a specific
chromatin conformation on the genome, of which post-
translational modifications of histone tails and CpG dinucle-
otidemethylation are the best characterized. Much attention
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and differentiation. The first evidence came from the obser-
vation that genes important for the maintenance of pluripo-
tency in embryonic stem cells (ESCs), such as OCT4 and
NANOG, are usually hypomethylated when activated,
whereas they become hypermethylated during differentia-
tion.9,10 High-throughput strategies for genome-wide DNA
profiling demonstrate that human ESCs have a unique CpG
methylation signature, which, in combination with histone
modifications, drives stem cell differentiation by restricting
the developmental potential of progenitor cells.11–13 The
epigenetic control of pluripotency is not restricted to the
classic pluripotency-related genes, because it has been
recently described that hypermethylation of tissue-specific
genes also controls the reprogramming ability of somatic
cells into pluripotent cells.14 In contrast with the wide-rang-
ing information obtained from ESCs, the role of CpG meth-
ylation in regulating differentiation of adult multipotent stem
cells has been less extensively examined.15 Adult stem
cells of different origin (eg, adipose tissue, bone marrow, or
hematopoietic progenitor cells) display a range of differen-
tiation potentials in mesodermal, endodermal, and ectoder-
mal tissues,16 and strong methylation of lineage-specifica-
tion promoters restricts the ability of adult stem cells of
different origin to differentiate.17 For example, methylation of
endothelial cell–specific genes (CD31 and CD144) has
been described in freshly isolated hASCs, but not in differ-
entiated cells, after endothelial stimulation.18 Preliminary ge-
nome-wide approaches, including gene expression, CpG
methylation, histone marks, and microRNA (miRNA) analy-
sis,19 allow a connection to be established between
changes in the epigenetic signature and progression from
pluripotent to multipotent cells, highlighting the existence of
specific epigenetic profiles associated with each degree of
differentiation potential. The epigenetic control of stem cell
differentiation is also reinforced by several in vitro experi-
mental studies with chromatin-modifying drugs. Specific
epigenetic treatments can alter the potential of pluripotent
and multipotent stem cells to differentiate into several lin-
eages.15 For example, the use of DNA demethylation treat-
ment (5-aza-2-deoxycytidine) promotes differentiation of
multipotent cells into cardiac myogenic cells20 and drives
the osteogenic differentiation of mesenchymal stem cells.21
Despite the knowledge about how to govern stem cell
differentiation, we still lack information about the degree of
similarity between stem cell derivatives and their normal
primary counterparts. The success of stem cell differentia-
tion is usually addressed by expression of a set of differen-
tiation markers and loss of pluripotency-related genes. In
addition, to achieve appropriate quality and control of these
cells, we must also ensure the integrity of the epigenome
and avoid inappropriate gene expression in transplanting
cells or tumorigenesis. Herein, we have performed a high-
throughput analysis using methylation arrays of well-char-
acterized and defined populations of hASCs before and
after in vitro induction of osteogenic and myogenic differen-
tiation. Most important, the CpG methylation profile of these
cells has been compared with those obtained from normal
primary cells and tumor samples. Overall, our results dem-
onstrate that hASCs generate osteogenic and myogenic
lineages that resemble the DNA methylome of primary tis-sues, but do not present the epigenetic hallmarks of cancer
cells. These findings suggest that the profile of CpG meth-
ylation could be used as a biomarker of efficient and safe
cell identity after stem cell reprogramming.
Materials and Methods
Human Adipose-Derived Stem Cell Populations
hASCs were established from the adipose tissue of patients
aged 30 to 55 years. Samples were obtained by minimally
invasive liposuction procedures. Donors previously gave
their written informed consent, in accordance with the
guidelines of the Ethics Committee of the Nuestra Señora
de la Salud Hospital (Granada, Spain). hASC lines were
established as previously described.22 Briefly, lipoaspirates
were digested with 0.075% collagenase type I (Invitrogen
SA, Barcelona, Spain) prepared in PBS containing 1% bo-
vine serum albumin for 1 hour at 37°C with constant shak-
ing, followed by filtration through a 100-m filter. After wash-
ing with PBS, cells were treated with erythrocyte lysis buffer.
Resultant cells were cultivated at 1000 cells/cm2 in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS). Cultures were washed with
buffer for 24 to 48 hours after plating to remove unattached
cells, and then refed with fresh medium. Only cells in pas-
sage 5 or 6 were used in these experiments. Positive and
negative surface markers for hASCs, defined by the Inter-
national Society for Cellular Therapy, were studied by fluo-
rescence-activated cell sorting (FACSCanto II Cytometer;
BD Biosciences, San Jose, CA). Cells were removed from
culture using a nonenzymatic cell dissociation solution (Sig-
ma-Aldrich, Madrid, Spain) and washed with PBS. The fol-
lowing antibodies were used: CD73, CD90, CD105, CD45,
CD34, and CD133 (BD Biosciences). Approximately 2 
105 cells were incubated with primary antibody directly cou-
pled to fluorescein isothiocyanate, allophycocyanin, or phy-
coerythrin for 15 minutes in the dark at room temperature.
In Vitro Differentiation
hASCs were differentiated to osteogenic and myogenic
lineages by in vitro induction using specific culture me-
dium.23 Osteogenesis was induced in the presence of
DMEM with 10% FBS, 0.1 mol/L dexamethasone, 10
mmol/L -glycerophosphate, and 50 g/mL ascorbic acid-
2-phosphate. After 28 days, the culture medium was re-
moved and cells were washed with PBS and processed.
Calcium deposition was visualized by alizarin red stain-
ing and confirmed by X-ray microanalysis of cultured
cells under the scanning electron microscope (SEM),
following the method of Kim et al.24 In addition, RT-PCR
analysis using mRNA obtained from total cells incubated
in osteogenic medium was performed to determine gene
expression of osteonectin, osteopontin, and osteocalcin.
Myogenic induction of hASCs was performed in the pres-
ence of DMEM with 10% FBS, 50 mol/L hydrocortisone,
and 5% horse serum. After 42 days, the degree of myo-
genic differentiation was analyzed by immunofluores-
cence using monoclonal antibodies against -sarco-
meric actin (clone 5C5; Sigma-Aldrich), -sarcomeric
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(clone C-19; Santa Cruz Biotechnology, Inc., Santa Cruz,
CA). In addition, RT-PCR analysis using mRNA of these
cells was used to determine gene expression of desmin,
myosin-1, and myogenic differentiation 1. A complemen-
tary study to determine the regression of osteogenic and
myogenic differentiation was performed by analyzing the
induced cells after removing the culture medium supple-
mented with the differentiation agents over 14 and 20
days for osteogenic and myogenic induction, respec-
tively. The RT-PCR primers and annealing temperatures
(Tm) used were as follows: desmin (Tm  51°C), 5=-
GGTGGAGGTGCTCACTAACC-3= (antisense) and 5=-
TGTTGTCCTGGTAGCCACTG-3= (antisense); myosin-
1 (Tm  51°C), 5=-TGTGAATGCCAAATGTGCTT-3=
(sense) and 5=-GTGGAGCTGGGTATCCTTGA-3= (antisense);
myogenic differentiation 1 (Tm  52°C), 5=-AAGCGC-
CATCTCTTGAGGTA-3= (sense) and 5=-GCGCCTTTATTTT-
GATCACC-3= (antisense); osteocalcin (Tm  56°C), 5=-
GCTCTAGAATGGCCCTCACACTC-3= (sense) and
5=-GCGATATCCTAGACCGGGCCGTAG-3= (antisense); os-
teonectin (Tm  53°C), 5=-TGTGGGAGCTAATCCTGTCC-3=
(sense) and 5=-TCAGGACGTTCTTGAGCCAGT-3= (anti-
sense); and osteopontin (Tm  50°C), 5=-GCTCTAGAAT-
GAGAATTGCACTG-3= (sense) and 5=-GTCAATGGAGTC-
CTGGCTGT-3= (antisense).
Cancer Cell Lines and Primary Tissues
The human rhabdomyosarcoma (RD and TE.32.7) and
osteosarcoma (MG-63) cell lines were obtained from
ATCC (Rockland, MD). Cell lines were maintained in
monolayer cultures at 37°C in an atmosphere containing
5% CO2, with DMEM supplemented with 10% FBS. Nor-
mal primary cells were obtained from biopsy specimens
of the rectus abdominis muscle (myocytes) and ribs (os-
teocytes) under histological validation, and the samples
were stored at 80°. All samples were obtained in ac-
cordance with the guidelines of the Ethics Committee of
the Bio-Health Research Foundation of Eastern Andalusia
(Granada, Spain).
DNA Methylation Profiling Using Universal Bead
Arrays
DNA from adipose-derived stem cells, in vitro–differentiated
cells, cancer cell lines, and primary tissues was isolated by
applying the QIAamp DNA Mini Kit (Qiagen, Iberia, Spain).
Microarray-based DNAmethylation profiling was performed
with the HumanMethylation2 BeadChip Infinium Methyl-
ation Arrays (Illumina, Inc.) on a total of five adipose-
derived stem cells, six in vitro–differentiated cells, three
normal primary tissues, and three cancer cell lines. The
panel was designed to compare the DNA methylation
status of each group of samples, which allow 27,578 CpG
loci covering 14,495 genes at single-nucleotide resolu-
tion to be interrogated by typing bisulfite-converted DNA.
The sequences included in the panel were derived from
the well-annotated National Cancer for Biotechnology In-
formation consensus coding sequence (CCDS) database(Genome Build 36) and were supplemented by 1000
cancer-related genes described in the literature. The
probe content was enriched to include 150 well-estab-
lished cancer genes known to show differential methyl-
ation patterns. The methylation array content also tar-
geted the promoter regions of 110 miRNA genes.
Methylation arrays were then performed. First, 1 g of
genomic DNA was bisulfite converted using the
CpGenomicTM DNA Modification Kit (Intergen Company,
Purchase, NY). After sodium bisulfite treatment, the re-
maining assay steps used Infinium technology (Illumina
Inc, San Diego, CA), previously described for single-
nucleotide polymorphism genotyping25 with manufactur-
ers’ supplied reagents and conditions. A thermocycling
program with a short denaturation step included for bisul-
fite conversion (16 cycles at 95°C for 30 seconds, fol-
lowed by 50°C for 1 hour) was performed to improve the
bisulfite conversion efficiency. After bisulfite conversion,
each sample was whole-genome amplified and enzymat-
ically fragmented. The bisulfite-converted whole-genome
amplified DNA samples were purified and applied to the
BeadChips (Illumina Inc, San Diego, CA). During hybrid-
ization, the whole-genome amplified DNA molecules an-
nealed to locus-specific DNA oligomers linked to individual
bead types. The two bead types corresponded to each
CpG locus: one to the methylated and the other to the
unmethylated state. Allele-specific primer annealing was
followed by single-base extension using dinitrophenyl- and
biotin-labeled dNTPs. Both bead types for the same CpG
locus incorporated the same type of labeled nucleotide,
determined by the base preceding the interrogated cyto-
sine in the CpG locus, and could, therefore, be detected in
the same color channel. After extension, the array was fluo-
rescently stained and scanned, and the intensities of the
unmethylated and methylated bead types were measured.
DNA methylation values, described as  values, were
recorded for each locus in each sample via BeadStudio
software (Illumina Inc). The DNA methylation  value is a
continuous variable between 0 (completely unmethy-
lated) and 1 (completely methylated), and represents the
ratio of the intensity of the methylated bead type/com-
bined locus intensity. The DNA methylation microarray
data are freely available for download from the National
Cancer for Biotechnology Information Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo; accession
number GSE33896).
Hierarchical Cluster Analysis and Definition of
CpG Methylation Differences
Hierarchical clustering was performed on all of the stud-
ied samples using the Cluster Analysis tool of the
BeadStudio software version 3.2 (Illumina Inc). CpGs in-
cluded in the analysis had to meet two criteria: a false-
discovery rate of 0.01 and not being located on the X
chromosome (to avoid a sex-specific bias). To investigate
the methylation profiles, we first excluded the CpGs with a
coefficient of variation of 0.25 for samples to discount
intrasample variation among those of the same category.
Averages were calculated from the resulting sequences.
2082 Berdasco et al
AJP December 2012, Vol. 181, No. 6Differentially methylated CpG sites were determined calcu-
lating the differences in average  values between groups.
A threshold of 0.20 change in average  values and a
false-discovery rate of0.01 in an analysis of variance test,
adjusted for multiple testing, was applied to assign signifi-
cant differentially methylated sites.26
Bisulfite Genomic Sequencing of Multiple
Clones
We determined the CpG island methylation status of the
selected genes by PCR analysis of bisulfite-modified
genomic DNA, which induces the chemical conversion of
unmethylated, but not methylated, cytosine to uracil. After
PCR and cloning, 10 clones of each sequence and sam-
ple were automatically sequenced to determine their de-
gree of methylation. Primer sequences and annealing
temperatures used were as follows: CD79B (Tm 59°C),
5=-GGGGTAAGTATAGATAGAGGGGA-3= (sense) and
5=-AATAAAAACAAACCCCACAAAC-3= (antisense); CDKL1
(Tm  59°C), 5=-CAAAATCATCTTCTAATTCCAAAA-3=
(sense) and 5=-TTAGTTTTTTGAGTTGTTGGGA-3= (anti-
sense); PIWI-like 2 (PIWIL2; Tm  58°C), 5=-GTAGGT-
TGGGTTTTTGTTTAAGT-3= (sense) and 5=-TAACCAA-
AAACAAAACCCC-3= (antisense); receptor-type tyrosine-
protein phosphatase S (PTPRS; Tm  58°C), 5=-TGT-
GGGGGAGATATTTTAATTT-3= (sense) and 5=-CCTT-
CTACTACACAACCTCCAA-3= (antisense); serum amyloid
A1 (SAA1; Tm  58°C), 5=-GTTTTGAGTGAGGTTTTGT-
TGT-3= (sense) and 5=-ATTTTCCCCAATTTATCAAATC-3=
(antisense); solute carrier family 44 member 2 (SLC44A2;
Tm  58°C), 5=-GGGTTTTTTAGTTTGGGTAGTT-3= (sense)
and 5=-TATTCTCTCAAAACCCCCTC-3= (antisense); and
transmembrane channel-like 8 (TMC8; Tm  62°C), 5=-
ACTCCRACACCCCAAAAA-3= (sense) and 5=-GTGT-
GTTTTTTTGAGAGTTGGAG-3= (antisense).
Expression Microarrays
For the expression microarray experiment in hASCs and
in vitro differentiated cells, total RNA was prepared using
TRIzol (Invitrogen, Carlsbad, CA) and further purified us-
ing RNeasy columns (Qiagen, GmbH, Germany), accord-
ing to the manufacturers’ instructions. The integrity of
RNA was monitored by both Byoanalyzer (Agilent, Santa
Clara, CA) and spectrometric measurement. Biotinylated
target RNA was prepared from 200 ng of total RNA using
the Affymetrix protocol (Affymetrix, Santa Clara, CA).
Briefly, double-stranded cDNA was prepared from the
RNA template using the Ambion WT Expression kit, fol-
lowing manufacturer’s instructions. The resulting comple-
mentary RNA target was randomly fragmented using
uracil DNA glycosylase and apurinic/apyrimidic endonu-
clease 1, labeled with the terminal transferase (WT Ter-
minal Labeling kit; Affymetrix) and hybridized on the Hu-
man Gene 1.1 ST 16-array (Affymetrix). The hybridization
reactions were processed and scanned according to the
standard GeneTitan (Affymetrix) protocols. All arrays
were globally scaled to a target intensity value of 100 and
then the scaling factor, background, noise, and percent-age present were calculated according to the Command
Console (AGCC 2.0) and Expression Console (EE 1.1)
software (Affymetrix, High Wycombe, UK). All resulting
data sets were filtered using the absolute call metric
(present or absent) using Microsoft Access (Microsoft
Corporation, Redmond, WA). The resulting values repre-
sent the transcript abundance (absolute value) following the
Affymetrix statistical procedure. Three biological replicates
were obtained for each ASC sample, and in vitro–differen-
tiated cells were analyzed in duplicate. The DNA expres-
sion microarray data are freely available for download from
NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.
gov/geo; accession number GSE37329).
Transcriptome Data Analysis
To identify all genes or probe sets whose expression was
significantly different between control adipose-derived stem
cells and each one of the two differentiated cell types (os-
teogenis or myogenic differentiation), we used the following
approach under R statistical language: the raw data coming
from the Affymetrix Human Gene 1.1 ST platform were pre-
processed and normalized using the Affymetrix package
(background subtraction and quantile normalization), then
the differential expression was assessed using a linear
model procedure (limma package).27 The differentially ex-
pressed genes with at least 20% expression increase (fold-
change 1.2) or 20% expression decrease (fold-change
0.8) after induction were selected, and the resultant
P values were adjusted for multiple testing using the Ben-
jamini and Hochberg correction procedure.
Gene Ontology Analysis
Gene ontology (GO) analysis of the selected genes was
performed using the Bioconductor package GOstats
(Bioconductor, Boston, MA).28 The set of selected genes
was tested for enrichment of any GO category, and the
P values for multiple testing were adjusted using the
Benjamini and Hochberg correction procedure.
Comparisons between Differentially Methylated
and Differentially Expressed Genes
Because of the fact that the genes differentially ex-
pressed and methylated are not the same for myogenic
and osteogenic lineages, we conducted a difference be-
tween two lists using their functional profiles. We used
squared euclidean distance to quantify the difference
between profiles26 and calculate P values.
RT-qPCR Expression Analysis
Total RNA was prepared from all samples using TRIzol
(Invitrogen, Carlsbad) and further purified using RNeasy
columns (Qiagen, GmbH), according to the manufacturers’
instructions. For quantitative RT-PCR assays, 2 g of total
RNA was converted to cDNA with the ThermoScriptTM
RT-PCR System (Invitrogen) using oligo-dT as primer.
PCR amplifications were performed as follows: 0.20 g of
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Master Mix (Applied Biosystems, Foster City, CA). Three
measurements were analyzed using a Prism 7700 Se-
quence Detection (Applied Biosystems) instrument.
Quantitative RT-PCR (RT-qPCR) primer sequences were
as follows: PIWIL2, 5=-GTGGGTTGAGCTCGGTCTT-3=
(sense) and 5=-GGACGGGCTGTAGAGAACAC-3= (anti-
sense); PTPRS, 5=-ACTCGGCCAACTACACCTG-
3= (sense) and 5=-GGCTGTGTTCTCAGTCACCA-3= (anti-
sense); and SAA1, 5=-AGCCGAAGCTTCTTTTCGTT-
3= (sense) and 5=-GCCGATGTAATTGGCTTCTC-3= (anti-
sense). Primer sequences for osteogenic differentiation
markers were as follows: osteopontin, 5=-CGCAGACCT-
GACATCCAGTA-3= (sense) and 5=-ATTCAACTCCT-
CGCTTTCCA-3= (antisense); and alkaline phosphatase, 5=-
TGAAATATGCCCTGGAGCTT-3= (sense) and 5=-TCACT-
GTGGAGACACCCATC-3= (antisense). Primer sequences
for myogenic differentiation markers were as follows:
desmin, 5=-TGATGGAATACCGACACCAG-3= (sense) and
5=-GCCTCATCAGGGAATCGTTA-3= (antisense); and myo-
cyte enhancer factor 2A, 5=-TGATGCGGAATCATA-
AAATCG-3= (sense) and 5=-GGCTGGTCACTGGAACT-
GTG-3= (antisense). Three independent measurements were
performed for each condition, and the SD was calculated.
RNA Interference
Three small-interfering RNA (siRNA) duplexes that recog-
nized three different sequences against the PIWIL2 gene
were designed. The siRNA primers were for the following
regions: 1, 5=-GTGGCCACAAGCTTCTAAACTTCAA-
GAGAGTTTAGAAGCTTGTGGCCATTTTTTACGCGT-3=
(sense) and 5=-ACGCGTAAAAAATGGCCACAAGCTTCTA-
AACTCTCTTGAAGTTTAGAAGCTTGTGGCCAC-3= (anti-
sense); 2, 5=-GTGCTAATCTGGTACGCAAGTTCAA-
GAGACTTGCGTACCAGATTAGCATTTTTTACGCGT-3=
(sense) and 5=-ACGCGTAAAAAATGCTAATCTGGTACG-
CAAGTCTCTTGAACTTGCGTACCAGATTAGCAC-3= (anti-
sense); and 3, 5=-GCCTACAAGTGCTATGGTACTTCAA-
GAGAGTACCATAGCACTTGTAGGTTTTTTACGCGT-3=
(sense) and 5=-ACGCGTAAAAAACCTACAAGTGCTATG-
GTACTCTCTTGAAGTACCATAGCACTTGTAGGC-3= (anti-
sense). As a negative control, the following scramble prim-
ers (a target with any complementary human coding
regions) were used: 5=-GCGCAGAACAAATTCGTCC-
ATTCAAGAGATGGACGAATTTGTTCTGCGTTTTTTAC-
GCGT-3= (sense) and 5=-ACGCGTAAAAAACGCA-
GAACAAATTCGTCCATCTCTTGAATGGACGAA-
TTTGTTCTGCGC-3= (antisense). The previously mentioned
siRNA oligonucleotides were cloned into a pLVX-shRNA2
lentivirus vector (Clontech, Mountain View, CA), following
supplier’s instructions. Green clones expressing fluores-
cent ZsGreen1 protein were selected for further experi-
ments. Silencing of PIWIL2 expression was confirmed by
protein blotting.
Western Blot Analysis
For Western blot analysis, we collected cells by centrifu-
gation, washed cell pellets twice with phosphate buffered
saline (PBS) buffer, and extracted total proteins withLaemmli buffer. Protein separation was performed on a
7.5% SDS-PAGE gel. Fractions were transferred to a ni-
trocellulose membrane with a 45-m pore size (Immo-
bilon PTM or Millipore filter; Millipore Ibérica, Madrid,
Spain), blocked in 5% milk PBS with 0.1% Tween-20, and
immunoprobed with the respective primary antibodies.
We used the corresponding horseradish enhanced
chemiluminescence (ECLTM) peroxidase–conjugated
antibody to IgG (GE Healthcare; Amersham, Pittsburgh,
PA) at 1:3000 dilution as a secondary antibody. Signals
were detected with an ECLTM Western blot detection
reagent (GE Healthcare; Amersham, Pittsburgh, PA). Pri-
mary antibody was used at 1:1000 dilution (ab85084;
Abcam, Cambridge, UK).
Results
Generation of Osteogenic and Myogenic
Lineages from Human Adipose-Derived Stem
Cells
hASCs were obtained from lipoaspirates according to the
criteria established by the International Society for Cellu-
lar Therapy for defining mesenchymal stem cells.29
hASCs grew as adherent spindle-shaped fibroblastoid
cells and were positive for CD73, CD90, and CD105
surface markers, and negative for CD34, CD45, and
CD133 (Figure 1A). hASCs were successfully differenti-
ated into osteogenic and myogenic lineages. Calcium de-
position was visualized by alizarin red staining in cells after
28 days of osteogenic induction (Figure 1B). Energy-
dispersive X-ray analysis in the SEM of these differen-
tiated cells confirmed the presence of this chemical
element (Figure 1B). Determination by RT-PCR of os-
teonectin, osteopontin, and osteocalcin gene expres-
sion was consistent with the osteogenic differentiation
process (Figure 1B). For the myogenic differentiation of
hASCs, the expression of established muscle-specific
markers was determined by immunofluorescence and
RT-PCR. As shown in Figure 1C, differentiated hASCs
were strongly stained for troponin T-C, -sarcomeric
actin, and actinin. Differentiation of hASCs into myo-
genic precursor cells was confirmed by the expression
of transcription factors, such as myogenic differentia-
tion 1, and structural proteins, such as myosin-1 and
desmin (Figure 1C).
DNA Methylation Changes Associated with
Osteogenic and Myogenic Differentiation of
Human Adipose-Derived Stem Cells
We analyzed the DNA methylation status of 27,578 CpG
sites of the human genome (Infinium 27K Illumina arrays)
in hASCs taken from different donors (n  4) compared
with hASC-derived osteocytes (known as in vitro osteo-
cytes; n  3) or hASC-derived myocytes (known as in
vitro myocytes; n  3). Unsupervised scatterplots of all of
rentiati
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samples and their corresponding osteogenic or myo-
genic differentiated cells revealed a high degree of sim-
ilarity in their CpG methylation patterns (Figure 2A). To
search for specific changes in the methylation status of
particular CpGs during both types of differentiation, we
used a threshold-based method using three replicates for
each sample and a 20% CpG methylation  value as
the cutoff. We obtained 108 differentially methylated CpG
dinucleotides between hASCs and in vitro–differentiated
cells: there were 85 differentially methylated CpG sites in
hASCs versus the myogenic lineage (see Supplemental
Table S1 at http://ajp.amjpathol.org), whereas 23 CpG
sites changed their methylation value after induction of
osteogenic differentiation in hASCs (see Supplemental
Table S2 at http://ajp.amjpathol.org), which enabled both
types of samples to be classified into distinct clustering
arms in the hierarchical analysis (Figure 2B). Among the
108 CpG sites, the CpG methylation shift most often
occurred in promoter-associated CpG islands [71 (66%)
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AJP December 2012, Vol. 181, No. 6induction of myogenic differentiation (Figure 2C). Likewise,
in the other differentiation pathway, the SAA1 5=-end CpG-
poor region was heavily methylated in hASCs and became
hypomethylated on the induction of osteogenic differentia-
tion (Figure 2C). In an opposite manner to these genes, the
5=-regulatory CpG island of PIWIL2 was essentially un-
methylated in hASCs, but it became densely methylated
when the cell became committed to both myogenic and
osteogenic pathways (Figure 2C).
The relevance of the described CpG methylation shifts
was reinforced by the study of the expression dynamics
of the previously mentioned genes. PTPRS and SAA1,
showing a hypermethylated 5=-end region in hASCs (a
CpG island for PTPRS and a CpG-poor region for SAA1),
both demonstrated an absence of their transcripts in the
mesenchymal stem cells, as determined by quantitative
real-time RT-PCR (Figure 2D). The CpG hypomethylation
events on differentiation previously described were asso-
ciated with a gain of expression of PTPRS and SAA1 in
myogenic and osteogenic differentiation, respectively
(Figure 2D). The expression profiles of PIWIL2 occurred
in the opposite manner to that of PTPRS and SAA1, and
they fit the corresponding DNA methylation changes: the
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Figure 2. Specific promoter methylation events during in vitro differentiation
values in a representative adipose-derived stem cell sample versus an in vitro
significantly differentially methylated CpGs after myogenic and osteogenic differ
of differentially methylated genes after induction of differentiation by bisulfi
dinucleotides around the transcription start site (long black arrow). CpG dinu
of 10 individual clones are shown. The presence of a methylated or unmethylat
each PTPRS, SAA1, and PIWIL2 mRNA relative to glyceraldehyde-3-phosphatePIWIL2 transcript was present in the mesenchymal un-methylated stem cells, but it was repressed on the induc-
tion of both lineages in association with the gain of PIWIL2
CpG island hypermethylation (Figure 2D).
To establish a functional consequence of the changes
in DNA methylation during differentiation, we analyzed
gene expression profiles using the Affymetrix Human
Gene 1.1 ST Array. We compared the expression of
hASCs (n  2) with the induced differentiated cells cor-
responding to myogenic (n  2) and osteogenic (n  2)
lineages, and we identified a set of genes differentially
expressed before and after differentiation (see Supple-
mental Table S4 and Supplemental Table S5 at http://
ajp.amjpathol.org). Because the genes differentially ex-
pressed and methylated were not exactly the same, we
conducted a difference between two lists using their
functional profiles using squared euclidean distance to
quantify the difference between profiles. The P values
associated with distance values are 0.05 (0.4616 and
0.6966 for myogenic and osteogenic lineages, respec-
tively), suggesting that no significant statistical differ-
ences could be established between methylation and
expression groups (ie, the two functional profiles in both
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AJP December 2012, Vol. 181, No. 6Plasticity of the Epigenetic Setting of Human
Adipose-Derived Stem Cells—Restoration of
DNA Methylation Patterns on Regression of the
Differentiation Process
Unlike the constrained genetic landscape, the epigenetic
profiles of cells and tissues adapted quickly to changes
in the surrounding microenvironment.33 We examined
how closely the observed DNA methylation patterns were
associated with the osteogenic and myogenic lineage
and whether a return to the adult stem cell stage was
linked to a shift in DNA methylation profiles. Therefore, we
evaluated the effect of deprivation of the induction factors
for osteogenic and myogenic differentiation in the culture
media. As shown in Figure 3A, osteogenic and myo-
genic cells cultured for 15 to 20 days in the absence of
differentiation agents lost the phenotypic features of
the lineage (eg, normal muscle typical cell alignment)
and recovered the morphological characteristics of the
original hASCs.
Most important, the regression to an adult stem cell
phenotype of the in vitro–differentiated cells was associ-
ated with a complete reversion of the DNA methylation
patterns (Figure 3B). If bisulfite genomic sequencing re-
vealed an unmethylated PTPRS promoter CpG island in
myogenic cells, it became hypermethylated on the depri-
vation of the differentiating factor (Figure 3B). Similarly, in
the other differentiation pathway, the SAA1 5=-end CpG-
poor region that was unmethylated in induced osteogenic
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Figure 3. Differentiated cells deprived of the induction factor reacquire
osteogenic and myogenic lineage showing significant morphological change
genomic sequencing of the promoter region of PTPRS, SAA1, and PIWIL2 ge
The results of bisulfite genomic sequencing of 10 individual clones are show
or white square, respectively. C: The expression levels of PTPRS, SAA1, an
detected by RT-qPCR in regressed cells.differentiation became hypermethylated on the regres-sion to adult stem cell status (Figure 3B). In contrast, the
5=-regulatory CpG island of PIWIL2 that was densely
methylated in both in vitro–differentiated lineages under-
went hypomethylated changes when the cells were de-
prived of the myogenic and osteogenic commitment fac-
tors in their growth media (Figure 3B). The importance of
CpG methylation dynamics was supported by the study
of the expression changes of the described genes.
PTPRS and SAA1, with an unmethylated 5=-end region in
the in vitro–induced myogenic and osteogenic cells, both
demonstrated a loss of their transcripts on regression to
mesenchymal stem cell status, as determined by quan-
titative real-time PCR (Figure 3C). The hypermethylation
of SAA1 in regressed cells did not correspond with the
low expression levels in ASCs. The poor-CpG promoter
content of SAA1 could justify this absence of linear cor-
relation between expression and CpG methylation. The
opposite correlation was observed for PIWIL2 transcrip-
tion: on withdrawal of the differentiating factor from the
two lineages, the adult stem cell phenotypic cells recov-
ered the expression of the PIWIL2 transcript (Figure 3C),
in association with the previously described PIWIL2 CpG
island hypomethylation events.
Once we demonstrated that PIWIL2 epigenetic silenc-
ing was associated with entrance into a differentiation
program, we assayed the effect of abrogation of
PIWIL2 expression by siRNA in our model. We stably
silenced PIWIL2 in adipose-derived stem cells by using
three different duplexes that recognized three different
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AJP December 2012, Vol. 181, No. 6expression was monitored by RT-PCR and Western blot
analysis (see Supplemental Figure S1 at http://ajp.
amjpathol.org). We observed that PIWIL2 silencing fa-
cilitated cellular differentiation. Specific markers for
myogenic differentiation appeared after 21 days of in-
duction in PIWIL2-depleted cells, instead of 42 days in
ASCs expressing PIWIL2 (see Supplemental Figure S1
at http://ajp.amjpathol.org), whereas osteogenic mark-
ers in si-PIWIL2 cells appeared at day 20, instead of
day 28 (see Supplemental Figure S1 at http://ajp.
amjpathol.org).
Distinct DNA Methylation Profile of Osteogenic
and Myogenic Lineages Derived from Human
Adipose Stem Cells and Primary Osteocytes
and Myocytes
To fulfill the promise of novel biomedical therapies based
on adult stem cells, a critical issue in the field was the
analysis of how closely related the in vitro–generated
differentiated cells were to the targeted primary tis-
sue.34,35 To address this question, we compared the
DNA methylation status of 27,578 CpG sites of the human
genome (Infinium 27K Illumina arrays) in the in vitro–
obtained osteogenic and myogenic lineages derived
from human adipose stem cells with that of freshly iso-
lated primary normal osteocytes and myocytes obtained
from healthy donors. Unsupervised scatterplots using all
of the CpG probes contained in the microarray revealed
significant differences in their CpG methylation patterns
(Figure 4A). To search for specific changes in the meth-
ylation status of particular CpGs during in vitro compared
with natural differentiation, we used a threshold-based
method involving three replicates for each sample and a
20% CpG methylation  value as a cutoff. This identi-
fied 4712 differentially methylated CpGs: there were 2313
differentially methylated CpG dinucleotides in the myo-
genic lineage relative to the hASCs (see Supplemental
Table S6 at http://ajp.amjpathol.org), whereas 2399 CpG
sites changed their methylation value after induction of
osteogenic differentiation in hASCs (see Supplemental
Table S7 at http://ajp.amjpathol.org), which enabled both
types of samples to be classified into distinct clustering
arms in the hierarchical analysis (Figure 4B). Among the
total 4712 CpG sites, the CpGmethylation shifts occurred
in CpG-poor promoters [3103 CpGs (66%)] and promoter-
associated CpG islands [1609 CpGs (34%)]. The most
common difference was a lower rate of CpG methylation
in the in vitro–differentiated cells than in the primary tis-
sues [2807 (60%) of 4712 CpGs] (Figure 4C). The type of
CpG methylation differences observed between in vitro–
differentiated and primary cells, according to the lineage,
are shown in Supplemental Figure S2 (available at http://
ajp.amjpathol.org). In addition, differentially methylated
genes between in vitro–differentiated cells (derived from
stem cells) and in vivo–differentiated cells (from donors)
were mostly enriched for GO terms associated with signal
transduction and system development. An enrichment of
defense and immune response (P  0.05) was also de-scribed in both myogenic and osteogenic lineages (see
Supplemental Table S3 at http://ajp.amjpathol.org).
We further validated the observed DNA methylation mi-
croarray data in in vitro–differentiated cells from adult stem
cells compared with primary tissues by bisulfite genomic
sequencing of multiple clones in differentially methylated
candidate genes. We selected four genes that represented
the two observed DNA methylation scenarios. The
SLC44A2 and CDKL1 genes had a 5=-end regulatory region
that was unmethylated in the respective osteogenic and
myogenic lineages (Figure 4D), but these regions were
densely methylated in their normal counterparts (Figure
4D). On the other hand, the CD79B and TMC8 genes
showed highly methylated 5= regions around their transcrip-
tion start sites in the stem cell–differentiated osteocytes and
myocytes (Figure 4D), but the primary osteocytes and myo-
cytes obtained from the volunteers were unmethylated for
the described sequences (Figure 4D).
Distinct DNA Methylation Profile of Osteogenic
and Myogenic Lineages Derived from Human
Adipose Stem Cells and Osteosarcoma and
Rhabdomyosarcoma Cells
To establish a possible clinical use for the in vitro–differ-
entiated cells originating from adult stem cells, it was also
extremely important to ensure that the obtained lineages
had not acquired a tumorigenic potential36–38 or that the
original adipose stem cells were not themselves carriers
of cancer-prone DNA methylation features.
To address this first question, we analyzed the DNA
methylation status of 27,578 CpG sites of the human ge-
nome (Infinium 27K Illumina arrays) in the in vitro–obtained
osteogenic and myogenic lineages derived from human
adipose stem cells compared with osteosarcoma and rhab-
domyosarcoma cells, respectively. Unsupervised scatter-
plots of all of the CpG probes contained in the microarray of
the osteogenic or myogenic differentiated lineages derived
from the adult stem samples revealed significant differ-
ences in the CpGmethylation patterns comparedwith those
of the corresponding transformed cells (Figure 5A). To
search for specific changes in the methylation status of
particular CpGs during in vitro differentiation that could be
shared with tumor cells, we used a threshold-basedmethod
using three replicates for each sample and a 20% CpG
methylation  value as a cutoff. By using this approach, we
obtained 7007 differentially methylated CpG sites between
the in vitro–differentiated lineages and the transformed
cells. A total of 2166 CpG dinucleotides were differentially
methylated in the myogenic lineage compared with the
rhabdomyosarcoma cells (see Supplemental Table S8 at
http://ajp.amjpathol.org), whereas 4841 CpG sites had a
different methylation value in in vitro–differentiated osteo-
cytes and osteosarcoma cells (see Supplemental Table S9
at http://ajp.amjpathol.org). This enabled both types of sam-
ples to be classified into distinct clustering arms in the
hierarchical analysis (Figure 5B). Among all 7007 CpG
sites, the CpG methylation shifts occurred in promoter-as-
sociated CpG islands [4161 CpGs (59%)] and CpG-poor
promoters [2846 CpGs (41%)]. However, there was clear
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AJP December 2012, Vol. 181, No. 6enrichment of methylation changes in CpG-rich promoters
associated with hypermethylation in tumorigenic samples
for the myogenic and osteogenic lineages (Fisher’s exact
test, two-tailed P  0.0001). The most common difference
was a higher frequency of CpG methylation in transformed
cells than in in vitro–differentiated cells [5096 (73%) of 7007
CpGs] (Figure 5C).
Finally, we compared the DNA methylation profiles of
the original adipose stem cells and of the myogenic and
osteogenic cancer cells to exclude the existence of sig-
nificant DNA methylation changes associated with cellu-
lar transformation39,40 in the adult stem cells. Unsuper-
vised scatterplots using all of the CpG probes contained
in the microarray revealed significant differences in their
CpG methylation patterns (Figure 5D). We found 7823
CpG sites to be differentially methylated in the adult stem
cells and the transformed cells. A total of 4024 CpG
dinucleotides were differentially methylated in hASCs
compared with rhabdomyosarcoma cells (see Supple-
mental Table S10 at http://ajp.amjpathol.org), whereas
3799 CpG sites had a different methylation value in adult
stem cells and osteosarcoma cells (see Supplemental
Table S11 at http://ajp.amjpathol.org). This enabled both
types of samples to be classified into distinct clustering
arms in the hierarchical analysis (Figure 5E). Among all
7823 CpG sites, the CpG methylation shifts occurred in
promoter-associated CpG islands [4300 CpGs (55%)]
and CpG-poor promoters [3523 CpGs (45%)]. Again, we
found significant enrichment of gain of methylation in tumor
samples specifically in CpG-rich promoters (Fisher’s exact
test, two-tailed P  0.0001). The most common difference
was a higher frequency of CpG methylation in the trans-
formed cells than in in vitro–differentiated cells [6531
(83%) of 7823 CpGs] (Figure 5F).
Referring to the functional clustering of differentially
methylated genes involving cancer cells, the GO analysis
demonstrated enrichments of genes mostly involved in
regulation of cellular processes, signal transduction, and
development (P  0.05) (see Supplemental Table S3 at
http://ajp.amjpathol.org).
Overall, our data showed that it is possible to generate
myogenic and osteogenic lineages from easily obtain-
able adipose stem cells that, according to a comprehen-
sive DNA methylation analysis of 27,578 CpG sites, re-
semble the corresponding primary differentiated tissues
and did not present the DNA methylation hallmarks of
cancer cells. This supported their putative use for trans-
lational and clinical purposes.
Figure 4. DNA methylation profile of in vitro–differentiated cells and the
methylation values in a representative sample from in vivo normal primary
cluster analysis and heat map showing the differential groups of CpGs accor
BeadChip Infinium Methylation Arrays are performed in normal primary tissu
bar). Methylation levels vary from fully methylated (red) to fully unmethylated
cells compared with primary tissues. The genomic distribution in CpG-rich
Promoter CpG methylation status of differentially methylated genes by bisulfi
islands around the transcription start site (long black arrow). The locatio
dinucleotides are represented as short vertical lines. The results of bisulfite genomic
or unmethylated cytosine is indicated by a black or white square, respectively.Discussion
The conversion of human pluripotent ESCs into diff-
erentiated somatic cells is believed to involve only
small changes in DNA methylation at promoter re-
gions.9,10,13,41,42 For instance, 8% of unmethylated CpGs
in hESCs became methylated after differentiation to neu-
ral precursors, whereas 2% of methylated CpGs in
hESCs lose methylation in neural precursors.41 Similar
results were described for adult stem cell differentiation:
80% of the promoter hypermethylation in differentiated
adipocytes (from adipose-derived stem cells) and myo-
cytes (from skeletal muscle–derived stem cells) was also
present in nondifferentiated cells. If we consider the small
proportion of sequences with differential methylation, the
silencing of specific pluripotency-related genes, such as
OCT4 or NANOG,9 by de novo promoter methylation is
well-known. Our results also demonstrate that stem cell
differentiation from hASCs involves changes in the meth-
ylation patterns of a few genes.
The epigenetic silencing of PIWIL2 in committed cells in
osteogenic andmyogenic lineages is of particular note. The
PIWI/Ago family is required for stem cell maintenance.25
PIWIL2, also known as MILI proteins, interacts with the epi-
genetic mechanism by controlling the RNA interference
mechanism.43,44 PIWI proteins bind to 24 to 31 nucleotide
PIWI-interacting RNAs and regulate germ line development,
stem cell maintenance, epigenetic regulation, and transpo-
sition.45–47 DNA methylation of Oct4 and Nanog promoters
could be a mechanism for preventing aberrant reactivation
of pluripotency and for minimizing the risk of dedifferentia-
tion.48 Our results suggest that PIWIL2 epigenetic control
must also be important for maintaining themultipotent ability
in adipose-derived stem cells.
Silencing of stemness-related genes is one critical
step in stem cell commitment, but we must also account
for the gain of expression of differentiation genes. Spe-
cific demethylation events are frequently linked to gene
activation on somatic differentiation, such as the reacti-
vation of tissue-specific genes (eg, Lrrtm2) coupled to
loss of promoter methylation in neural differentiation from
mouse ESCs.13 We found that PTPRS, a protein with a
role in neuronal and lymphoblastoid differentiation,49,50
and SAA1, which is involved in osteogenic differentia-
tion,23 behaved in the same way in hASC-derived differ-
entiation. It remains uncertain how DNA methylation
could contribute to tissue-specific gene expression and
differentiation. There are a few studies investigating the
link between DNAmethylation of CpG-rich promoters and
tissue-specific gene expression, and a small, but signif-
nding normal primary tissues. A: Two-dimensional scatterplots of Infinium
rom rib and muscle) versus each in vitro–differentiated cell. B: Supervised
heir DNA methylation profile in all analyzed samples. HumanMethylation27
ribs and muscle (green bar) and in in vitro myocytes and osteocytes (yellow
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AJP December 2012, Vol. 181, No. 6icant, proportion of genes have been identified as differ-
entially methylated among cell types.51–53 The expres-
sion of the human MASPIN (SERPINB5) gene is limited to
certain types of epithelial cells, but no detectable
amounts of the gene are found in skin fibroblasts, lym-
phocytes, bone marrow, heart, or kidney.52 Consistent
with this finding, other genes, such as rSPHK1 and
hSLC6A8, showed promoter hypermethylation associ-
ated with gene silencing in specific tissues.51,54 Further-
more, recent studies identified tissue-specific differen-
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Our results suggest that DNA methylation profiles could
be used as a biomarker of appropriate differentiation. How-
ever, the results also reinforce the dynamic nature of epi-
genetic regulation under certain environmental signals, as
was demonstrated by the reversion of the DNA methylation
levels of PTPRS, SAA1, and PIWIL2 genes in the deprivation
experiments. Are some genes (or chromosomal regions)
more epigenetically stable than others? A recent article
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AJP December 2012, Vol. 181, No. 6adult stem cells to initiate osteogenic differentiation. Fan et
al57 described how a mutation in BCL6 corepressor
(BCOR), a transcriptional repressor of the activating protein
2 AP2, induces osteogenesis through histone modifica-
tions. Thus, we revised the methylation levels of BCOR in
our 27K Illumina assays, and confirmed that BCOR is highly
methylated in normal bone (methylation value, 0.95) but
hemimethylated in in vitro osteocytes (methylation value,
0.44). This partial epigenetic reprogramming of hASC-de-
rived cells could also explain the possibility of regression in
the first steps of differentiation, as we demonstrated in our
deprivation experiments. Indeed, under certain experimen-
tal conditions, a mature cell can be converted into a pluri-
potent state by the in vitro application of a defined set of
transcription factors controlled by promoter hypermethyl-
ation, generating induced pluripotent stem cells.58–60 Fur-
thermore, the recent finding that somatic cells can be re-
programmed to pluripotency merely by overexpressing
certain ESC-specific miRNAs that target differentiation
genes,61 together with the role of specific miRNAs in cell
differentiation (ie, miR-1 and miR-206 in myogenic differen-
tiation),62 suggests that epigenetic control plays a far more
important role in differentiation than previously suspected.
Finally, one critical step in the development of stem
cell–based therapies in regenerative medicine is the
ability to manipulate stem cells into differentiated cells,
ensuring cell identity after reprogramming and mini-
mizing the risk of tumorigenesis. In contrast to the
well-addressed genomic instability in ESC deriva-
tives,63 reports of malignant transformation of adult
stem cells are scarce, but spontaneous oncogenic
transformation has been described in some long-term
cultured stem cells, which is one of the requisites for
transplantation purposes.64,65 A complex two-step
model has recently been proposed that involves alter-
ations in cell cycle, mitochondrial metabolism, and
DNA repair, together with oncogene expression and
silencing of tumor-suppressor genes, by which a mes-
enchymal stem cell becomes a tumor cell.66 In addi-
tion, clonal chromosomal aberrations may also arise
transiently in early passage of hASC cultures.67
The question arises as to whether DNA methylation is
altered during large-scale culture of hASCs. Only a few
DNA methylation–dependent genes are affected by the
passage number of hASCs under specific culture condi-
tions. Dahl et al68 did not find any significant change in the
DNA methylation status of specific promoters. They com-
pared DNA methylation in bone marrow stem cells with
freshly isolated and cultured hASCs and showed that most
genes unmethylated in both bone marrow stem cells and
hASCs during early passage are also unmethylated in un-
cultured hASCs. Herein, we also assessed the risk of tumor-
igenesis of adipose-derived stem cells and their derivatives
by comparing their methylation patterns with those obtained
from tumor samples (rhabdomyosarcoma and osteosar-
coma cell lines). Aberrant DNAmethylation patterns, includ-
ing hypermethylation of tumor suppressor genes, are one of
the main hallmarks of cancer cells.69,70 Our methylation ar-
ray, which is enriched in CpGs representing CpG islands on
promoter regions, allows the hypermethylation profiles of stem
cells and cancer cells to be examined. Our results suggestthat the genome-wide hypermethylation profile of hASCs and
deriveddifferentiatedcells stronglydiffers from that obtained in
cancer cell lines, indicating that the tumorigenic properties of
specific stem cell populations66 could be generated by CpG
methylation–independent mechanisms.
Overall, our data demonstrate that myogenic and os-
teogenic cells derived from adipose stem cells acquire
part of the DNA methylation setting of the primary corre-
sponding differentiated tissues, but neither of them fea-
tures the DNA methylation profiles of transformed cells.
Most notably, our results highlight the necessity of per-
forming appropriate molecular tests to ensure the integ-
rity of the epigenome in any candidate cell line or tissue
intended for use in regenerative therapy.
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